One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
- :
Price : 100$- Special Price : 50$
Translating AI innovation into clinical practice
doi : 10.1016/S2665-9913(25)00161-4
Jul 2025 Volume 7Number 7e451-e520
Why is progressive ILD in systemic sclerosis so difficult to predict?
Treatment outcomes in VEXAS syndrome: response is in the eye of the definer
Autoimmune disease in pregnancy: strengthening research and care
The use of IL-1 and IL-6 inhibitors should be prioritised in Still's disease
The use of IL-1 and IL-6 inhibitors should be prioritised in Still's disease – Authors' reply
Predicting the risk of subsequent progression in patients with systemic sclerosis-associated interstitial lung disease with progression: a multicentre observational cohort study
Treatment outcomes in patients with VEXAS syndrome: a retrospective cohort study
Long-term effect of anifrolumab on patient-reported outcomes in systemic lupus erythematosus (TULIP-LTE): a randomised, placebo-controlled, phase 3 long-term extension trial
Trends in the prevalence of autoimmune diseases during pregnancy in the UK, 2000–21: a retrospective cohort study
ERN ReCONNET–SLICC–SLEuro expert consensus on the therapeutic management of rare systemic lupus erythematosus manifestations
